ArticleCancer2025
Survival outcomes of pulmonary metastasis-directed local therapy in adenoid cystic carcinoma.
Article in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- PRAME promotes invasion and metastasis of salivary adenoid cystic carcinoma by regulating RARα stability via the cullin2 ubiquitin-proteasome system.Clinical and translational medicine · 2026Article
- On the Statistical Limitations of Landmark Analysis for Addressing Immortal Time Bias.Statistics in medicine · 2026Article
- Resection of Liver Metastasis from Lacrimal Gland Adenoid Cystic Carcinoma: A Case Report and Review of the Literature.Surgical case reports · 2026Article
- Surgical resection for pulmonary metastases from head and neck adenoid cystic carcinoma: a propensity-matched survival analysis.Journal of cancer research and clinical oncology · 2025Observational
- Survival outcomes of pulmonary metastasis-directed local therapy in adenoid cystic carcinoma.Cancer · 2025Article
- Proton therapy achieves high-dose tumor control with organ preservation in complex metastatic adenoid cystic carcinoma: a case report of a refractory patient with 16 pulmonary metastases.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundAdenoid cystic carcinoma (ACC) frequently has pulmonary metastasis (PM). Given limited systemic therapy options, these metastases are often treated with pulmonary metastasis-directed local therapy (PM-LT), although with unknown impact on overall survival (OS). This single institution, retrospective cohort study investigated the survival outcomes of PM-LT versus no PM-LT in ACC.
methodsACC patients with at least one PM (≥5 mm) were included. PM-LT was metastasectomy or radiotherapy. Clinicopathologic characteristics were compared between patients with and without PM-LT. Primary end point was OS from PM diagnosis, with landmark analysis at 6 months, 1 year, 2 years, and 3 years after metastasis diagnosis, with Cox proportional hazards model multivariate analysis and propensity score matching analysis. Subgroup analysis by ACC histology (solid/nonsolid) was performed.
resultsOf 219 included ACC, 119 (54%) had no PM-LT and 100 (46%) did. PM-LT patients had more nonsolid histology (p = .0008), oligometastases (p < .0001), exclusively PM (p = .02), and longer time to metastasis from diagnosis (p < .0001). On univariate analysis, PM-LT by 6 months, 1 year, and 2 years, but not by 3 years, increased OS. On multivariate analysis, PM-LT by 6 months (p = .12), 1 year (p = .08), or 3 years (p = .08) did not significantly increase OS, but PM-LT by 2-years had a borderline statistically significant association (p = .045). Of the 104 nonsolid ACC, 50 underwent PM-LT and 54 did not. On univariate and multivariate analysis, PM-LT did not increase OS at any time point for nonsolid ACC.
conclusionThis is the largest study of survival outcomes of PM-LT in metastatic ACC. Findings suggest PM-LT does not increase OS in unselected ACC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.